US2904573A - Ferrous citrate complex - Google Patents

Ferrous citrate complex Download PDF

Info

Publication number
US2904573A
US2904573A US657042A US65704257A US2904573A US 2904573 A US2904573 A US 2904573A US 657042 A US657042 A US 657042A US 65704257 A US65704257 A US 65704257A US 2904573 A US2904573 A US 2904573A
Authority
US
United States
Prior art keywords
iron
ferrous
complex
parts
diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US657042A
Inventor
Oroshnik William
William H Haffcke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Priority to US657042A priority Critical patent/US2904573A/en
Priority to CH5274457A priority patent/CH367593A/en
Application granted granted Critical
Publication of US2904573A publication Critical patent/US2904573A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/295Iron group metal compounds

Definitions

  • This invention relates to a new therapeutically effective compound for providing a source of iron in the diet and more particularly relates to a new therapeutic compound in the nature of a ferrous salt of citric acid,
  • ferrous compounds such as ferrous sulfate consistently causes some degree of digestive discomfort.
  • a compound having the empirical formula Fe (C H O -10H O and the structural formula in which the ten molecules of water are bound by coordinate covalences may be prepared from citric acid or ferrous acid citrate by reacting either compound with the stoichiometric quantity of powdered iron required to produce triferrous dicitrate.
  • the complex is a very slightly colored powder and is very stable to air oxidation, the ferrous content remaining substantially ungen is continued throughout the reaction and the mixture is stirred and heated to C. during a period of two hours and maintained at that temperature for an additional two or three hours.
  • an additional 55.9 parts (1 mole) of reduced powdered iron is added and stirring is continued under nitrogen while maintaining the reaction temperature at 80 C. until the total reaction time is 24 hours.
  • the mixture is suction-filtered whilehot.
  • the filtered cake is washed with water until free from chloride ion and then three times with an equal volume of isopropanol.
  • the product is dried at 50 C. for six hours.
  • the yield is 650 parts (90% calculated as the decahydrate) of white crystalline material.
  • the product so obtained is analyzed for carbon, hydrogen, and iron.
  • T riferrous dicitrate decahydrate One hundred seventeen and four-tenths parts (0.445 mole) of the monoferrous acid citrate monohydrate obtained from Example 11 above is added to 500 parts of water, and air is displaced from the reaction kettle with nitrogen as described above. To this suspension is added 12.4 parts (0.223 mole) of powdered iron and the mixture is stirred and heated at 85 -90 C. for 24 hours. The product is filtered off, washed with water, then with acetone, and air dried. One hundred twenty-nine parts of a crystalline product similar to the product obtained in Example I is recovered. The product so obtained had the final analysis:
  • the complex may be uniformly distributed in a suitable vehicle and formed into a tablet.
  • Inert diluents or fillers are chosen which are chemically compatible with the complex. Satisfactory diluents include lactose, dextrose, sucrose, sodium chloride, glycine, kaolin and starch.
  • a binder such as acacia, zein, tragacanth, gelatin, sodium carboxymethylcellulose, or methylcellulose and also, in order that a tablet may be readily prepared, that a lubricant such as magnesium stearate, zinc stearate, mineral oil, stearic acid, stearyl alcohol or monoand polyglycol esters also be intimately admixed with the filler and active agent.
  • a lubricant such as magnesium stearate, zinc stearate, mineral oil, stearic acid, stearyl alcohol or monoand polyglycol esters also be intimately admixed with the filler and active agent.
  • the above ingredients, including the complex may be formed into a tablet by thoroughly mixing the ingredients in a moist condition, granulating and compressing the mixture into tablets by conventional methods.
  • Additives such as tricalcium citrate may be used alone or with inert diluents if it is desired to supply calcium along with the iron in
  • a composition of matter in dosage unit form for oral administration effective as a source of iron in the diet which comprises a ferrous citrate complex having the formula Fe (C H O -1OH O in intimate admixture with an inert solid diluent.
  • a process for the preparation of a triferrous dicitrate complex having associated therewith water of hydration comprising the steps of adding powdered iron to a suspension of monoferrous acid citrate in water and heating the mixture whereby the complex is formed and precipitated, and removing the precipitated complex.

Description

United States Patent FERROUS CITRATE COMPLEX No Drawing. Application May 6, 1957 Serial No. 657,042
3 Claims. (Cl. 260-439) This invention relates to a new therapeutically effective compound for providing a source of iron in the diet and more particularly relates to a new therapeutic compound in the nature of a ferrous salt of citric acid,
Heretofore, it has been the established practice to administer iron in the form of ferrous sulfate to provide a source of iron in the diet of humans where indicated. Supplemental sources of iron are frequently required by anemic, pregnant, and aged patients.
It has been frequently observed that the administration in the diet of ferrous compounds such as ferrous sulfate consistently causes some degree of digestive discomfort. Youm ans, Journal of the American Medical Association, volume 143, page 1252, 1950; summarized the undesirable features due to the addition of ferrous compounds in the diet by stating that patients undergoing such treatment traditionally complain of gastro-intestinal symptoms, nausea, cramps, diarrhea and epigastric distress from taking iron; but if the patients persist in continuing to take iron, the symptoms usually disappear, probably due to an acquired tolerance,
2,904,573 a e ted S pt.- 5, 5.9
ice
2 changed after six months of storage in air at ordinary temperatures in the absence of direct light. However, removal of the water by vacuum desiccation at elevated or room temperature results in spontaneous auto-oxidation of the complex with the conversion of the ferrous iron of the complex to the ferric state. The dehydrated compounds continue to oxidize to the ferric state when allowed to stand at room temperature even in the absence of light. The structure of thev dehydrated compound or of the mixture of compounds formed on dehydration is not known but X-ray diffraction patterns and chemical analysis show it to be an entirely different chemical entity from that of the hydrated material having the above formula.
The following examples are set forth for the purpose of illustrating the method of preparing the ferrous citrate complex and compositions of matter in dosage unit form according to this invention but are not to be construed as a limitation. All parts are given by weight unless otherwise indicated.
EXAMPLE I Triferrous dicitrate decahydrate In a reaction kettle equipped with a stirrer, reflux condenser, and gas inlet, tube reaching below the expected liquid level, is placed 420 parts 2 moles) of citric acid monohydrate and 2000 parts of water. The solution is stirred at room temperature while nitrogen is passed in, and when the'air is displaced from the kettle (about 30 minutes) 111.7 parts (2 moles) of reduced powdered iron is added rapidly. The introduction of nitro- Iron preparations in liquid form, and solutions of ferrous sulfate in particular, are offensive to taste. Ferrous compounds are unstable and are readily oxidized to the ferric form on exposure to the atmosphere.
It is an object of this invention to provide a stable, therapeutic compound in the nature of a ferrous salt of citric acid.
It is another objectof this invention to provide a stable, therapeutic compound containing all of the chemically bound iron in the ferrous state which upon oral administration is utilized normally without gastro-intestinal disturbances, constipation or diarrhea.
It is still another object of this invention to provide a new and improved therapeutic tablet effective by oral administration in providing a supplemental source of iron in the diet.
Other and further objects of this invention will be apparent from the description to follow, the examples and the appended claims.
It has now been discovered that a compound having the empirical formula Fe (C H O -10H O and the structural formula in which the ten molecules of water are bound by coordinate covalences, may be prepared from citric acid or ferrous acid citrate by reacting either compound with the stoichiometric quantity of powdered iron required to produce triferrous dicitrate. The complex is a very slightly colored powder and is very stable to air oxidation, the ferrous content remaining substantially ungen is continued throughout the reaction and the mixture is stirred and heated to C. during a period of two hours and maintained at that temperature for an additional two or three hours. When the reaction is completed, as indicated by the disappearance of unreacted iron particles, an additional 55.9 parts (1 mole) of reduced powdered iron is added and stirring is continued under nitrogen while maintaining the reaction temperature at 80 C. until the total reaction time is 24 hours.
At the end of this period, the mixture is suction-filtered whilehot. The filtered cake is washed with water until free from chloride ion and then three times with an equal volume of isopropanol. The product is dried at 50 C. for six hours. The yield is 650 parts (90% calculated as the decahydrate) of white crystalline material.
The product so obtained is analyzed for carbon, hydrogen, and iron.
Found, Theory for percent the decahydrate, percent Carbon 20.02 19. Hydrogen 4. 15 4. 17 Iron 23. 16 23. 08
The above analysis corresponds most closely to the decahydrate.
EXAMPLE II Monoferrous acid citrate monohydrate hundred twenty-one parts of the dry product is recovered. The product so obtained is analyzed for carbon, hydrogen, and iron.
T riferrous dicitrate decahydrate One hundred seventeen and four-tenths parts (0.445 mole) of the monoferrous acid citrate monohydrate obtained from Example 11 above is added to 500 parts of water, and air is displaced from the reaction kettle with nitrogen as described above. To this suspension is added 12.4 parts (0.223 mole) of powdered iron and the mixture is stirred and heated at 85 -90 C. for 24 hours. The product is filtered off, washed with water, then with acetone, and air dried. One hundred twenty-nine parts of a crystalline product similar to the product obtained in Example I is recovered. The product so obtained had the final analysis:
In employing the ferrous citrate complex of the present invention for the provision of a source of iron in the diet, the complex may be uniformly distributed in a suitable vehicle and formed into a tablet. Inert diluents or fillers are chosen which are chemically compatible with the complex. Satisfactory diluents include lactose, dextrose, sucrose, sodium chloride, glycine, kaolin and starch. It is desirable that a binder such as acacia, zein, tragacanth, gelatin, sodium carboxymethylcellulose, or methylcellulose and also, in order that a tablet may be readily prepared, that a lubricant such as magnesium stearate, zinc stearate, mineral oil, stearic acid, stearyl alcohol or monoand polyglycol esters also be intimately admixed with the filler and active agent. The above ingredients, including the complex, may be formed into a tablet by thoroughly mixing the ingredients in a moist condition, granulating and compressing the mixture into tablets by conventional methods. Additives such as tricalcium citrate may be used alone or with inert diluents if it is desired to supply calcium along with the iron in the tablet or formulation.
EXAMPLE IV Milligrams F3(C5H507)21OH20 Ca (C I-I O Dipotassium phosphate 50 Acacia 5O Magnesium stearate 30 Lactose -L EXAMPLE V F63(C5H507)2' Ca (C H O Dipotassium phosphate 100 Acacia 50 Magnesium stearate 3O Lactose 70 The novel ferrous citrate complex to which the present invention is directed, has been found to have value for the provision of a source of iron where the administration of this element in the diet is indicated and is particularly valuable for oral administration in the diet of anemic, pregnant, and aged individuals. 7 Since certain changes in carrying out the above process and certain modifications in the compositions which embody the invention may be made without departing from its scope, it is intended that all matter contained in the description shall be interpreted as illustrative and not in a limiting sense.
This application is a continuation-in-part of application Serial No. 617,943 filed October 24, 1956, now abancloned.
What is claimed is:
l. Triferrous dicitrate decahydrate.
2. A composition of matter in dosage unit form for oral administration effective as a source of iron in the diet which comprises a ferrous citrate complex having the formula Fe (C H O -1OH O in intimate admixture with an inert solid diluent.
3. A process for the preparation of a triferrous dicitrate complex having associated therewith water of hydration; comprising the steps of adding powdered iron to a suspension of monoferrous acid citrate in water and heating the mixture whereby the complex is formed and precipitated, and removing the precipitated complex.
References Cited in the file of this patent UNITED STATES PATENTS 2,621,201 Opfermann V Dec. 9, 1952

Claims (1)

1. TRIFERROUS DICITRATE DECAHYDRATE.
US657042A 1957-05-06 1957-05-06 Ferrous citrate complex Expired - Lifetime US2904573A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US657042A US2904573A (en) 1957-05-06 1957-05-06 Ferrous citrate complex
CH5274457A CH367593A (en) 1957-05-06 1957-11-16 Process for the preparation of a ferrocitrate complex

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US657042A US2904573A (en) 1957-05-06 1957-05-06 Ferrous citrate complex

Publications (1)

Publication Number Publication Date
US2904573A true US2904573A (en) 1959-09-15

Family

ID=24635617

Family Applications (1)

Application Number Title Priority Date Filing Date
US657042A Expired - Lifetime US2904573A (en) 1957-05-06 1957-05-06 Ferrous citrate complex

Country Status (2)

Country Link
US (1) US2904573A (en)
CH (1) CH367593A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091626A (en) * 1960-06-20 1963-05-28 Scherer Corp R P Method of making ferrous citrate
US4292324A (en) * 1974-05-02 1981-09-29 Aktiebolaget Draco Aqueous zinc solutions for medical use
US4400535A (en) * 1980-01-17 1983-08-23 Dr. Madaus & Co. Acidic alkali citrate and compositions for adjusting the pH of urine
US4575502A (en) * 1982-10-22 1986-03-11 National Research Development Corporation Pharmaceutical compositions
US4894455A (en) * 1983-10-31 1990-01-16 National Research Development Corporation Pharmaceutically active zinc complexes
US5028411A (en) * 1984-04-19 1991-07-02 National Research Development Corporation Pharmaceutical compositions
US5206265A (en) * 1987-09-14 1993-04-27 Schering Aktiengesellschaft Iron citrate complex, process for its production, and its pharmaceutical
USRE37534E1 (en) 1982-10-22 2002-01-29 Btg International Limited Pharmaceutical compositions
US20080033196A1 (en) * 2006-08-04 2008-02-07 Swee-Keng Goh Metal carboxylate salts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2621201A (en) * 1949-09-13 1952-12-09 Johann G W Opfermann & Sohn Manufacture of ferro-calcium-citrate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2621201A (en) * 1949-09-13 1952-12-09 Johann G W Opfermann & Sohn Manufacture of ferro-calcium-citrate

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091626A (en) * 1960-06-20 1963-05-28 Scherer Corp R P Method of making ferrous citrate
US4292324A (en) * 1974-05-02 1981-09-29 Aktiebolaget Draco Aqueous zinc solutions for medical use
US4400535A (en) * 1980-01-17 1983-08-23 Dr. Madaus & Co. Acidic alkali citrate and compositions for adjusting the pH of urine
US4575502A (en) * 1982-10-22 1986-03-11 National Research Development Corporation Pharmaceutical compositions
US4834983A (en) * 1982-10-22 1989-05-30 National Research Development Corporation Pharmaceutical compositions
US4861767A (en) * 1982-10-22 1989-08-29 National Research Corporation Pharmaceutical compositions
USRE37534E1 (en) 1982-10-22 2002-01-29 Btg International Limited Pharmaceutical compositions
US4894455A (en) * 1983-10-31 1990-01-16 National Research Development Corporation Pharmaceutically active zinc complexes
US5028411A (en) * 1984-04-19 1991-07-02 National Research Development Corporation Pharmaceutical compositions
US5206265A (en) * 1987-09-14 1993-04-27 Schering Aktiengesellschaft Iron citrate complex, process for its production, and its pharmaceutical
US20080033196A1 (en) * 2006-08-04 2008-02-07 Swee-Keng Goh Metal carboxylate salts
US7495117B2 (en) 2006-08-04 2009-02-24 Kemin Industries, Inc. Metal carboxylate salts

Also Published As

Publication number Publication date
CH367593A (en) 1963-02-28

Similar Documents

Publication Publication Date Title
US2904573A (en) Ferrous citrate complex
AT366050B (en) METHOD FOR PRODUCING A HYDRATED CRYSTALLINE FORM OF THE SODIUM SALT OF AN OXIDE DERIVATIVE OF THE 7-AMINOTHIAZOLYL ACETAMIDOCEPHALOSPO RANIC ACID
JPH0532370B2 (en)
DE2444532A1 (en) METFORMIN ACETYL SALICYLATE
US2848366A (en) Non-hydrated ferrous fumarate and hematinic composition thereof
US2812344A (en) Ferrous calcium citrate complex
US2877253A (en) Therapeutic iron complex
US3830824A (en) Physiological organic acid silver allantoinates
JPS6028811B2 (en) Novel aluminum compound, its production method, and therapeutic agent for phosphate stone disease containing this compound
JPS59148789A (en) Manufacture of highly crystalline sodium cephoperazone
US3478073A (en) Preparation of anhydrous ferrous fumarate
JPH0567638B2 (en)
US2823166A (en) Choline ascorbate, methods for producing same, and compositions thereof
US3870792A (en) Certain dihydrophthalizines for treating hemorrhage and thrombosis
Kraus et al. Reactions Of Strongly Electropositive Metals With Organic Substances In Liquid Ammonia Solution. Iv. Action Of The Alkali Metals On Triphenylmethyl And Its Compounds
DE944943C (en) Process for the preparation of sodium perborate trihydrate
US3064038A (en) Process for preparing sodium acetylsalicylate
US2260870A (en) Medicinal preparation
US3064010A (en) Production of sodium isoascorbate monohydrate
DE1119249B (en) Process for the production of an oxidation-resistant and ferric salt-free monoferrodicalcium citrate containing water of crystallization
BE542824A (en)
US3840662A (en) Method of treating atherosclerosis using 4-hydroxymethyl-1-keto-1,2-dihydrophthalazine or acid salts thereof
JPS6289664A (en) Norfloxacin salt, manufacture and composition
DE2033997A1 (en) New alpha (p chlorophenoxy) isobutter acid derivatives
DE2038836A1 (en) drug